Effect of oral sucrose shortly before exercise on work capacity in McArdle disease

Archives of Neurology

Volumn 65, Issue 6, 2008, Pages 786-789

  Andersen, Susanne Tvede ^a   Haller, Ronald G ^b   Vissing, John ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SUCROSE;

ADULT; ARTICLE; BLOOD SAMPLING; CHEMICAL ANALYSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DNA DETERMINATION; DRUG BIOAVAILABILITY; DRUG EFFECT; EXERCISE; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; GLYCOGEN STORAGE DISEASE TYPE 5; HEART RATE; HUMAN; MALE; OUTCOME ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; THERAPY EFFECT; WORK CAPACITY;

ADMINISTRATION, ORAL; ADULT; BLOOD GLUCOSE; CROSS-OVER STUDIES; EXERCISE; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; GLYCOGEN STORAGE DISEASE TYPE V; HUMANS; MALE; MIDDLE AGED; SUCROSE; WORK CAPACITY EVALUATION;

EID: 45149131139     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.65.6.786     Document Type: Article

References (12)

1. DiMauro S, Hays AP, Tsujino S. Nonlysosomal glycogenoses. In: Engel AG, Franzini-Armstrong C, eds. Myology. New York: McGraw-Hill Inc; 2004:1535-1558.
2. Vissing J, Haller RG. A diagnostic cycle test for McArdle's disease. Ann Neurol. 2003;54(4):539-542.
3. Haller RG, Vissing J. Spontaneous "second wind" and glucose-induced second "second wind" in McArdle's disease: oxidative mechanisms. Arch Neurol. 2002;59(9):1395-1402.
4. Vissing J, Haller RG. The effect of oral sucrose on exercise tolerance in patients with McArdle's disease. N Engl J Med. 2003;349(26):2503-2509.
5. Andersen ST, Dunø M, Schwartz M, Vissing J. Do carriers of PYGM mutations have symptoms of McArdle disease? Neurology. 2006;67(4):716-718.
6. Borg G. Perceived exertion as an indicator of somatic stress. Scand J Rehabil Med. 1970;2(2):92-98.
7. Haller RG, Wyrick P, Taivassalo T, Vissing J. Aerobic conditioning: an effective therapy in McArdle's disease. Ann Neurol. 2006;59(6):922-928.
8. MacLean D, Vissing J, Vissing SF, Haller RG. Oral branched-chain amino acids do not improve exercise capacity in McArdle's disease. Neurology. 1998;51(5):1456-1459.
9. Vorgerd M, Zange J, Kley R, et al. Effect of high-dose creatine therapy on symptoms of exercise intolerance in McArdle's disease: double blind, placebo-controlled crossover study. Arch Neurol. 2002;59(1):97-101.
10. 6 supplementation in McArdle's disease: a strategic case study. Neuromuscul Disord. 1998;8(3-4):210-212.
11. Steele IC, Patterson VH, Nicholls DP. A double blind, placebo controlled, crossover trial of D-ribose in McArdle's disease. J Neurol Sci. 1996;136(1-2):174-177.
12. Pari G, Crerar MM, Nalbantoglu J, et al. Myophosphorylase gene transfer in McArdle's disease myoblasts in vitro. Neurology. 1999;53(6):1352-1354.